Kura Oncology Inc (KURA NASDAQ) stock market data APIs
$9.4628
-0.07(-0.7%)
as of May 8, 2026
Try our APIs with
free plan!
Kura Oncology Inc Financial Data Overview
Price chart is built with
Anychart
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Prev. Close
9.4628
Open
9.3884
High
9.563
Low
9.3154
52 wk Range
5.45-12.49
Market Cap
836 M
Shares Outstanding
88 763 K
Revenue
67 482 K
EPS
0
Beta
0.316
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Kura Oncology Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Kura Oncology Inc data using free add-ons & libraries
Get Kura Oncology Inc Fundamental Data
Kura Oncology Inc Fundamental data includes:
- Net Revenue: 67 482 K
- EBITDA: -302 599 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-04-30
- EPS/Forecast: -0.903
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Kura Oncology Inc News
New
Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates
Celldex Therapeutics (CLDX) came out with a quarterly loss of $1.18 per share versus the Zacks Consensus Estimate of a loss of $1.1. This compares to a loss of $0.81 per share a year ago. These figure...
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
SAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, tod...
Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML
– Regulatory Filing in Japan Planned Following Clinical Trial Completion – TOKYO and SAN DIEGO, April 24, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) and Kura On...
KURA Stock Rallies 8% on Strong Preliminary Renal Cancer Study Data
Shares of Kura Oncology KURA rose 8% after the company announced encouraging preliminary data from the ongoing FIT-001 study evaluating darlifarnib in combination with cabozantinib. The analysis focus...
Get Kura Oncology Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
